Related Experiment Video
Updated: May 10, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects
Paul G Richardson1, Tomer M Mark, Martha Q Lacy
1Dana-Farber Cancer Institute, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
Critical Reviews in Oncology/Hematology
|June 22, 2013
Summary
Pomalidomide offers a new treatment for relapsed multiple myeloma (MM) patients refractory to other therapies. Clinical trials show it provides durable responses with manageable side effects, including rare neuropathy.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Patients with relapsed or refractory MM require novel therapeutic strategies.
- Existing treatments like thalidomide, lenalidomide, and bortezomib have limitations.
Purpose of the Study:
- To evaluate the efficacy and safety of pomalidomide in patients with relapsed/refractory multiple myeloma.
- To assess pomalidomide's role as a second-generation immunomodulatory agent.
Main Methods:
- Phase I, II, and III clinical trials were conducted.
- Pomalidomide was administered at doses of 2-4 mg daily, continuously or cyclically.
- Pomalidomide was studied in combination with dexamethasone.
Main Results:
- Pomalidomide demonstrated promising response rates in relapsed/refractory MM patients.
- Combination therapy with dexamethasone yielded high-quality, durable clinical responses.
- Pomalidomide was generally well-tolerated, with manageable hematologic toxicities and rare peripheral neuropathy.
Conclusions:
- Pomalidomide is an effective treatment option for patients with relapsed and refractory multiple myeloma.
- Pomalidomide offers a favorable safety profile, with manageable adverse events.
- Further Phase III trials are ongoing to optimize pomalidomide treatment regimens.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:20Proliferative Phase
The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...